InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
PPH | Ann: Pushpay welcomes Michael Erisman as Chief People Officer | 21/03/19 | 0 | 31 | |||
|
|||||||
PPH | Ann: Pushpay’s revenue up 35.2%, gross margin percentage... | 07/02/19 | 0 | 114 | |||
|
|||||||
PPH | Ann: Pushpay Quarterly Investor Briefing | 09/01/19 | 0 | 156 | |||
|
|||||||
PPH | Ann: Pushpay achieves cash flow breakeven target, now... | 07/01/19 | 0 | 157 | |||
|
|||||||
PPH | Ann: Ongoing Disclosure Notice - James Maiocco | 31/12/18 | 0 | 158 | |||
|
|||||||
PPH | Ann: Ongoing Disclosure Notice - Kevin James Kuck | 31/12/18 | 0 | 133 | |||
|
|||||||
PPH | Ann: Ongoing Disclosure Notice - Guy Gregory Weismantel | 31/12/18 | 0 | 131 | |||
|
|||||||
PPH | Ann: Ongoing Disclosure Notice - Stephen Parker Basden | 31/12/18 | 0 | 133 | |||
|
See All Discussions